ClinicalTrials.gg
Status unknownNCT04544319Updated Sep 11, 2020

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

A Phase 1 interventional study of Zemiglo 50mg and Forxiga 10mg and Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg in T2DM, sponsored by LG Chem. Status unknown. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-11.

Sponsored by LG Chem · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg

Read the detailed description

To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg Also we identify safety and tolerance of FDC and each component

02

Conditions studied

  • T2DM
03

In context

Lead sponsor

LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults who are 19 years \~ 50 years when they are screened
  2. weight: 55.0 kg \~ 90.0 kg and : 18.0 kg/m2 \~ 30.0 kg/m2
  3. Volunteers who understand the procedures of clinical trial and signed form
  4. Volunteers who are eligible decided by vital signs, physical examination, lab test and 12-lead
  5. Women of chlidbearing potential have negative results in pregnancy test

Exclusion criteria

Exclusion Criteria:

  1. Healtjy volunteers who don't have disease such as liver disease, severe renal disease, acute pancreatitis... etc
  2. Drug Allergy in aspirin, NSAID, Anti-bacterial drugs
  3. GI tract diseases which affect PK results and safety such as ulceritis, GERD, chron disease...
  4. Chronic urine track infection
  5. Allergy history in sunset yellow 5 pigment and Fast green FCF (pigment)
  6. galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
  7. These resluts are appeared when screening

    • , AST >= 1.5
    • HbsAg, anti-, Ag\&Ab positive
    • equation: eGFR\< 60 mL/min/1.73m2
    • > 450 ms
    • Fasting serum glucose \< 70mg/dL or >110mg/dL
    • >6.5%
  8. SBP\<90mmHg or >150mmHg, DBP \<60mmHg or >100mmHg
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Arm I

    Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg

    Drug: Zemiglo 50mg and Forxiga 10mg · Drug: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg

  • Experimental
    Arm II

    Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg

    Drug: Zemiglo 50mg and Forxiga 10mg · Drug: Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg

Interventions

  • DrugZemiglo 50mg and Forxiga 10mg

    Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD

    Also known as: zemiglo and Forxiga

  • DrugFixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg

    Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD

    Also known as: zemiglo and Forxiga

06

What researchers measure

Primary outcomes

  1. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour)

  2. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 0.25hour

  3. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 0.5hour

  4. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 0.75hour

  5. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 1hour

  6. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 1.5hour

  7. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 2hour

  8. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 3hour

  9. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 4hour

  10. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 6hour

  11. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 8hour

  12. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 10hour

  13. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 12hour

  14. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 24hour

  15. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 36hour

  16. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 48hour

  17. Gemigliptin and dapagliflozin AUClast and Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Day 1 72hour

Secondary outcomes

  1. Gemigliptin and dapagliflozin AUCinf

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  2. Gemigliptin and dapagliflozin Tmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  3. Gemigliptin and dapagliflozin t1/2

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  4. Gemigliptin and dapagliflozin CL/F

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  5. Gemigliptin and dapagliflozin V/F

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  6. Gemigliptin metabolite(LC15-0636) AUClast

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  7. Gemigliptin metabolite(LC15-0636) Cmax

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 h), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  8. Gemigliptin metabolite(LC15-0636) AUCinf

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  9. Gemigliptin metabolite(LC15-0636) t1/2

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

  10. Gemigliptin metabolite(LC15-0636) metabolic ratio

    each phase 17 times blood sampling, total 34 times blood sampling

    Time frame: Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2020; primary completion for Mar 2021, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2020
First posted
Sep 10, 2020
StartEst.
Oct 2020
Primary completionEst.
Mar 2021
CompletionEst.
Jul 2021
Last update
Sep 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04544319
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Oct 2020 (estimated)
Primary completion
Mar 2021 (estimated)
Completion
Jul 2021 (estimated)
Last update
Sep 11, 2020

Study contacts

songyi park
Contact
songyi-park@lgchem.com
02-6987-4195
clinical LG Chem
Contact
lgclinical@lgchem.com
seunghwan Lee
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion